{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-164890","form_type":"8-K","ticker":"NTLA","cik":"0001652130","company_name":"Intellia Therapeutics, Inc.","filed_at":"2023-06-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.852765+00:00","generated_at":"2026-06-14T02:58:05.653983+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"NTLA-2002 Phase 1 data: 95% mean HAE attack reduction; 9 of 10 patients attack free","bullets":["Single 25-75 mg dose of NTLA-2002 (n=10) produced 95% mean reduction in monthly HAE attack rate through median 9-month follow-up.","All 9 patients achieving >60% plasma kallikrein reduction remain completely attack free since 16-week observation; longest attack-free interval 13.0 months.","All 6 patients who discontinued long-term HAE prophylaxis after NTLA-2002 have reported no subsequent attacks.","Safety: no dose-limiting toxicities, no serious adverse events, no Grade 3+ events; most adverse events mild and transient.","Phase 2 portion of study now dosing; Intellia expects to complete enrollment in H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-164890","json":"https://secwatch.observer/filing/0001193125-23-164890.json","markdown":"https://secwatch.observer/filing/0001193125-23-164890.md","text":"https://secwatch.observer/filing/0001193125-23-164890.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652130/000119312523164890/0001193125-23-164890-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652130/000119312523164890/d517852d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T02:58:05.653983+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}